Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Status:
Not yet recruiting
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201
positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an
integrated circulating tumor DNA (ctDNA) biomarker.